References
- Catlett J P, Williams S A, O'Connor S C, Krishnan J, Malkovska V. Primary lymphoma of bone: an institutional experience. Leuk Lymphoma 2008; 49: 2125–2132
- Heyning F H, Hogendoorn P C, Kramer M H, Hermans J, Kluin-Nelemans J C, Noordijk E M, Kluin P M. Primary non-Hodgkin's lymphoma of bone: a clinicopathological investigation of 60 cases. Leukemia 1999; 13: 2094–2098
- Beal K, Allen L, Yahalom J. Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients. Cancer 2006; 106: 2652–2656
- Horsman J M, Thomas J, Hough R, Hancock B W. Primary bone lymphoma: a retrospective analysis. Int J Oncol 2006; 28: 1571–1575
- Ramadan K M, Shenkier T, Sehn L H, Gascoyne R D, Connors J M. A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency. Ann Oncol 2007; 18: 129–135
- Park Y H, Kim S, Choi S J, Ryoo B Y, Yang S H, Cheon G J, Choi C W, Lim S M, Yoo J Y, Lee S S. Clinical impact of whole-body FDG-PET for evaluation of response and therapeutic decision-making of primary lymphoma of bone. Ann Oncol 2005; 16: 1401–1402
- Coleman R E, Guise T A, Lipton A, Roodman G D, Berenson J R, Body J J, Boyce B F, Calvi L M, Hadji P, McCloskey E V, et al. Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res 2008; 14: 6387–6395
- Power D G, McVey G P, Korpanty G, Treacy A, Dervan P, O'Keane C, Carney D N. Primary bone lymphoma: single institution case series. Ir J Med Sci 2008; 177: 247–251
- Ishikawa C, Matsuda T, Okudaira T, Tomita M, Kawakami H, Tanaka Y, Masuda M, Ohshiro K, Ohta T, Mori N. Bisphosphonate incadronate inhibits growth of human T-cell leukaemia virus type I-infected T-cell lines and primary adult T-cell leukaemia cells by interfering with the mevalonate pathway. Br J Haematol 2007; 136: 424–432
- Guise T A. Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat Rev 2008; 34(Suppl 1)S19–S24
- Winter M C, Thorpe H C, Burkinshaw R, Beevers S J, Coleman R E. The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathological response exploratory evidence for direct anti-tumor activity in breast cancer, 31st Annual San Antonio Breast Cancer Symposium 2008 2008: Abstract No. 5101
- Takasaki H, Kanamori H, Takabayashi M, Yamaji S, Koharazawa H, Taguchi J, Fujimaki K, Ishigatsubo Y. Non-Hodgkin's lymphoma presenting as multiple bone lesions and hypercalcemia. Am J Hematol 2006; 81: 439–442
- Lenz G, Wright G, Dave S S, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359: 2313–2323
- Adams H, Tzankov A, d'Hondt S, Jundt G, Dirnhofer S, Went P. Primary diffuse large B-cell lymphomas of the bone: prognostic relevance of protein expression and clinical factors. Hum Pathol 2008; 39: 1323–1330